Magnetic resonance spectroscopy in cognitive research

Brain Research Reviews

Volumn 44, Issue 2-3, 2004, Pages 83-102

  Ross, Amy J ^a   Sachdev, Perminder S ^b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b NONE

Author keywords

Cognition; Cognitive disorders; Magnetic resonance spectroscopy; N acetyl aspartate; Neural basis of behavior; Neuropsychological tests

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AMINO ACID; CHOLINE; CREATINE; CREATINE PHOSPHATE; GLUTAMINE; GLYCEROPHOSPHORYLCHOLINE; INOSITOL; LACTIC ACID; LEVODOPA; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; NEUROTRANSMITTER; PHOSPHOLIPID DERIVATIVE; PHOSPHORUS; PHOSPHORYLCHOLINE; PROTON; TETRAMETHYLAMMONIUM; XANOMELINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AEROBIC METABOLISM; AGING; ALZHEIMER DISEASE; AUTISM; BRAIN INJURY; BRAIN MEMBRANE; BRAIN REGION; BRAIN SURGERY; CELL VIABILITY; CHILDHOOD DISEASE; COGNITION; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DOWN SYNDROME; EMBASE; EPILEPSY; HUMAN; LOBECTOMY; LONGITUDINAL STUDY; MEDLINE; METABOLISM; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NERVE CELL; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PATHOLOGY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCINFO; REVIEW; SCHIZOPHRENIA; SYSTEMIC LUPUS ERYTHEMATOSUS; VERBAL MEMORY; WILLIAMS BEUREN SYNDROME; WORKING MEMORY;

ANIMALS; BRAIN; COGNITION; COGNITION DISORDERS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 1442323745     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2003.11.001     Document Type: Review

References (205)

1. Adalsteinsson E., Sullivan E.V., Kleinhans N., Spielman D.M., Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet. 355:2000;1696-1697.
2. Anderson B., Elgavish G.A., Chu W.J., Simor T., Martin R.C., Hugg J.W., Kuzniecky R.I. Temporal lobe pHi and IQ: no consistent correlation. Intelligence. 26:1998;75-79.
3. Barker P.B., Lee R.R., McArthur J.C. AIDS dementia complex: evaluation with proton MR spectroscopic imaging. Radiology. 195:1995;58-64.
4. Bartha R., Williamson P.C., Drost D.J., Malla A., Carr T.J., Cortese L., Canaran G., Rylett R.J., Neufeld R.W. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 54:1997;959-965.
5. 1H-magnetic resonance spectroscopy, brain volumetry and genetic polymorphisms in humans with memory impairment. Neurosci. Lett. 327:2002;177-180.
6. 1H MRS studies in vivo. NeuroReport. 7:1996;1397-1400.
7. Bertolino A., Nawroz S., Mattay V.S., Barnett A.S., Duyn J.H., Moonen C.T., Frank J.A., Tedeschi G., Weinberger D.R. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry. 153:1996;1554-1563.
8. Bertolino A., Callicott J.H., Elman I., Mattay V.S., Tedeschi G., Frank J.A., Breier A., Weinberger D.R. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol. Psychiatry. 43:1998;641-648.
9. Bertolino A., Callicott J.H., Nawroz S., Mattay V.S., Duyn J.H., Tedeschi G., Frank J.A., Weinberger D.R. Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia. Neuropsychopharmacology. 18:1998;1-9.
10. Bertolino A., Kumra S., Callicott J.H., Mattay V.S., Lestz R.M., Jacobsen L., Barnett I.S., Duyn J.H., Frank J.A., Rapoport J.L., Weinberger D.R. Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry. 155:1998;1376-1383.
11. Bertolino A., Esposito G., Callicott J.H., Mattay V.S., Van Horn J.D., Frank J.A., Berman K.F., Weinberger D.R. Specific relationship between prefrontal neuronal N-acetyl aspartate and activation of the working memory cortical network in schizophrenia. Am. J. Psychiatry. 157:2000;26-33.
12. Bertolino A., Sciota D., Brudaglio F., Altamura M., Blasi G., Bellomo A., Antonucci N., Callicott J.H., Goldberg T.E., Scarabino T., Weinberger D.R., Nardini M. Working memory deficits and levels of N-acetyl aspartate in patients with schizophreniform disorder. Am. J. Psychiatry. 160:2003;483-489.
13. Bothwell J.H., Rae C., Dixon R.M., Styles P., Bhakoo K.K. Hypo-osmotic swelling-activated release of organic osmolytes in brain slices: implications for brain oedema in vivo. J. Neurochem. 77:2001;1632-1640.
14. Bottomley P.A., Cousins J.P., Pendrey D.L., Wagle W.A., Hardy C.J., Eames F.A., McCaffrey R.J., Thompson D.A. Alzheimer dementia: quantification of energy metabolism and mobile phosphoesters with P-31 NMR spectroscopy. Radiology. 183:1992;695-699.
15. Braak H., Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol. Scand. Suppl. 165:1996;3-12.
16. Braus D.F., Ende G., Weber-Fahr W., Demirakca T., Tost H., Henn F.A. Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur. Neuropsychopharmacol. 12:2002;145-152.
17. Brenner R.E., Munro P.M., Williams S.C., Bell J.D., Barker G.J., Hawkins C.P., Landon D.N., McDonald W.I. The proton NMR spectrum in acute EAE: the significance of the change in the Cho: Cr ratio. Magn. Reson. Med. 29:1993;737-745.
18. Brenner T., Freier M.C., Holshouser B.A., Burley T., Ashwal S. Predicting neuropsychologic outcome after traumatic brain injury in children. Pediatr. Neurol. 28:2003;104-114.
19. Brooks W.M., Sabet A., Sibbitt W.L., Barker P.B., van Zijl P.C., Duyn J.H., Moonen C.T. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus. J. Rheumatol. 24:1997;2323-2329.
20. 1H-MRS differentiates white matter hyperintensities in subcortical arteriosclerotic encephalopathy from those in normal elderly. Stroke. 28:1997;1940-1943.
21. Brooks W.M., Jung R.E., Ford C.C., Greinel E.J., Sibbitt W.L. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J. Rheumatol. 26:1999;81-85.
22. Brooks W.M., Stidley C.A., Petropoulos H., Jung R.E., Weers D.C., Friedman S.D., Barlow M.A., Sibbitt W.L., Yeo R.A. Metabolic and cognitive response to human traumatic brain injury: a quantitative proton magnetic resonance study. J. Neurotrauma. 17:2000;629-640.
23. 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology. 39:1989;1423-1427.
24. Buchli R., Duc C.O., Martin E., Boesiger P. Assessment of absolute metabolite concentrations in human tissue by 31P MRS in vivo: Part I. Cerebrum, cerebellum, cerebral gray and white matter. Magn. Reson. Med. 32:1994;447-452.
25. 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol. Psychiatry. 36:1994;792-800.
26. Callicott J.H., Bertolino A., Egan M.F., Mattay V.S., Langheim F.J., Weinberger D.R. Selective relationship between prefrontal N-acetyl aspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry. 157:2000;1646-1651.
27. Callicott J.H., Bertolino A., Mattay V.S., Langheim F.J., Duyn J., Coppola R., Goldberg T.E., Weinberger D.R. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex. 10:2000;1078-1092.
28. Carlson S., Martinkauppi S., Rama P., Salli E., Korvenoja A., Aronen H.J. Distribution of cortical activation during visuospatial n-back tasks as revealed by functional magnetic resonance imaging. Cereb. Cortex. 8:1998;743-752.
29. Carter C., Robertson L., Nordahl T., Chaderjian M., Kraft L., O'Shora-Celaya L. Spatial working memory deficits and their relationship to negative symptoms in unmedicated schizophrenia patients. Biol. Psychiatry. 40:1996;930-932.
30. Catani M., Cherubini A., Howard R., Tarducci R., Pelliccioli G.P., Piccirilli M., Gobbi G., Senin U., Meek J.L. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. NeuroReport. 12:2001;2315-2317.
31. Catani M., Mecocci P., Tarducci R., Howard R., Pelliccioli G.P., Mariani E., Metastasio A., Benedetti C., Senin U., Cherubini A. Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease. J Am. Geriatr. Soc. 50:2002;1707-1710.
32. Chakraborty G., Mekala P., Yahya D., Wu G., Ledeen R.W. Intraneuronal N-acetyl aspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J. Neurochem. 78:2001;736-745.
33. Chang L., Ernst T., Leonido-Yee M., Walot I., Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology. 52:1999;100-108.
34. Chang L., Ernst T., Leonido-Yee M., Witt M., Speck O., Walot I., Miller E.N. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology. 53:1999;782-789.
35. Chang L., Ernst T., Witt M.D., Ames N., Gaiefsky M., Miller E. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. NeuroImage. 17:2002;1638-1648.
36. Chantal S., Labelle M., Bouchard R.W., Braun C.M.J., Boulanger Y. Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. Arch. Neurol. 59:2002;955-962.
37. Chen W., Hu J. Mapping brain metabolites using a double echo-filter metabolite imaging (DEFMI) technique. J. Magn. Reson. 140:1999;363-370.
38. Chih C.P., Lipton P., Roberts E.L. Jr. Do active cerebral neurons really use lactate rather than glucose? Trends Neurosci. 24:2001;573-578.
39. 1H magnetic resonance spectroscopy. Invest. Radiol. 30:1995;502-506.
40. Chong W.K., Sweeney B., Wilkinson I.D., Paley M., Hall-Craggs M.A., Kendall B.E., Shepard J.K., Beecham M., Miller R.F., Weller I.V. Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings. Radiology. 188:1993;119-124.
41. Christiansen P., Schlosser A., Henriksen O. Reduced N-acetyl aspartate content in the frontal part of the brain in patients with probable Alzheimer's disease. Magn. Reson. Imaging. 13:1995;457-462.
42. Colla M., Ende G., Bohrer M., Deuschle M., Kronenberg G., Henn F., Heuser I. MR spectroscopy in Alzheimer's disease: gender differences in probabilistic learning capacity. Neurobiol. Aging. 24:2003;545-552.
43. Cucurella M.G., Rovira A., Rio J., Pedraza S., Tintore M.M., Montalban X., Alonso J. Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR Biomed. 13:2000;57-63.
44. Cuenod C.A., Kaplan D.B., Michot J.L., Jehenson P., Leroy-Willig A., Forette F., Syrota A., Boller F. Phospholipid abnormalities in early Alzheimer's disease. In vivo phosphorus 31 magnetic resonance spectroscopy. Arch. Neurol. 52:1995;89-94.
45. D'Adamo A.F., Gidez L.I., Yatsu F.M. Acetyl transport mechanisms. Involvement of N-acetyl aspartic acid in de novo fatty acid biosynthesis in the developing rat brain. Exp. Brain Res. 5:1968;267-273.
46. Davie C.A., Feinstein A., Kartsounis L.D., Barker G.J., McHugh N.J., Walport M.J., Ron M.A., Moseley I.F., McDonald W.I., Miller D.H. Proton magnetic resonance spectroscopy of systemic lupus erythematosus involving the central nervous system. J. Neurol. 242:1995;522-528.
47. Deary I.J., Caryl P.G. Neuroscience and human intelligence differences. Trends Neurosci. 20:1997;365-371.
48. 1H MRS of the human brain addressed by one and the same data-analysis protocol. Magn. Reson. Imaging. 16:1998;1107-1111.
49. Deicken R.F., Merrin E.L., Floyd T.C., Weiner M.W. Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia. Schizophr. Res. 14:1995;177-181.
50. Deicken R.F., Zhou L., Corwin F., Vinogradov S., Weiner M.W. Decreased left frontal lobe N-acetyl aspartate in schizophrenia. Am. J. Psychiatry. 154:1997;688-690.
51. Deicken R.F., Zhou L., Schuff N., Fein G., Weiner M.W. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol. Psychiatry. 43:1998;483-488.
52. Deicken R.F., Pegues M., Amend D. Reduced hippocampal N-acetyl aspartate without volume loss in schizophrenia. Schizophr. Res. 37:1999;217-223.
53. De Stefano N., Matthews P.M., Arnold D.L. Reversible decreases in N-acetyl aspartate after acute brain injury. Magn. Reson. Med. 34:1995;721-727.
54. De Stefano N., Matthews P.M., Fu L., Narayanan S., Stanley J., Francis G.S., Antel J.P., Arnold D.L. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain. 121:1998;1469-1477.
55. De Stefano N., Narayanan S., Francis G.S., Arnaoutelis R., Tartaglia M.C., Antel J.P., Matthews P.M., Arnold D.L. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch. Neurol. 58:2001;65-70.
56. Dixon R.M., Bradley K.M., Budge M.M., Styles P., Smith A.D. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain. 125:2002;2332-2341.
57. Doraiswamy P.M., Charles H.C., Krishnan K.R. Prediction of cognitive decline in early Alzheimer's disease. Lancet. 352:1998;1678-1679.
58. Droz B., Di Giamberardino L., Koenig H.L., Boyenval J., Hassig R. Axon-myelin transfer of phospholipid components in the course of their axonal transport as visualized by radioautography. Brain Res. 155:1978;347-353.
59. Ebisu T., Rooney W.D., Graham S.H., Mancuso A., Weiner M.W., Maudsley A.A. MR spectroscopic imaging and diffusion-weighted MRI for early detection of kainate-induced status epilepticus in the rat. Magn. Reson. Med. 36:1996;821-828.
60. Ellis C.M., Lemmens G., Williams S.C., Simmons A., Dawson J., Leigh P.N., Chaudhuri K.R. Changes in putamen N-acetyl aspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology. 49:1997;438-444.
61. Erecinska M., Silver I.A. ATP and brain function. J. Cereb. Blood Flow Metab. 9:1989;2-19.
62. Erecinska M., Silver I.A. Metabolism and role of glutamate in mammalian brain. Prog. Neurobiol. 35:1990;245-296.
63. Everall I.P., Luthert P.J., Lantos P.L. Neuronal loss in the frontal cortex in HIV infection. Lancet. 337:1991;1119-1121.
64. Falini A., Calabrese G., Origgi D., Lipari S., Triulzi F., Losa M., Scotti G. Proton magnetic resonance spectroscopy and intracranial tumours: clinical perspectives. J. Neurol. 243:1996;706-714.
65. Ferguson K.J., MacLullich A.M.J., Marshall I., Deary I.J., Starr J.M., Seckl J.R., Wardlaw J.M. Magnetic resonance spectroscopy and cognitive function in healthy elderly men. Brain. 125:2002;2743-2749.
66. Ferrier C.H., Alarcon G., Glover A., Koutroumanidis M., Morris R.G., Simmons A., Elwes R.D., Cox T., Binnie C.D., Polkey C.E. N-acetyl aspartate and creatine levels measured by (1)H MRS relate to recognition memory. Neurology. 55:2000;1874-1883.
67. Fisher S.K., Novak J.E., Agranoff B.W. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J. Neurochem. 82:2002;736-754.
68. Foong J., Rozewicz L., Davie C.A., Thompson A.J., Miller D.H., Ron M.A. Correlates of executive function in multiple sclerosis: the use of magnetic resonance spectroscopy as an index of focal pathology. J. Neuropsychiat. Clin. Neurosci. 11:1999;45-50.
69. Frahm J., Krueger G., Merboldt K.D., Kleinschmidt A. Dynamic NMR studies of perfusion and oxidative metabolism during focal brain activation. Adv. Exp. Med. Biol. 413:1997;195-203.
70. Frederick B.B., Satlin A., Yurgelun-Todd D.A., Renshaw P.F. In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes. Biol. Psychiatry. 42:1997;147-150.
71. Frederick B., Satlin A., Wald L.L., Hennen J., Bodick N., Renshaw P.F. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. Am. J. Geriatr. Psychiatry. 10:2002;81-88.
72. Friedman S.D., Brooks W.M., Jung R.E., Hart B.L., Yeo R.A. Proton MR spectroscopic findings correspond to neuropsychological function in traumatic brain injury. Am. J. Neuroradiol. 19:1998;1879-1885.
73. Friedman S.D., Brooks W.M., Jung R.E., Chiulli S.J., Sloan J.H., Montoya B.T., Hart B.L., Yeo R.A. Quantitative proton MRS predicts outcome after traumatic brain injury. Neurology. 52:1999;1384-1391.
74. Fu L., Matthews P.M., De Stefano N., Worsley K.J., Narayanan S., Francis G.S., Antel J.P., Wolfson C., Arnold D.L. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain. 121:1998;103-113.
75. Fukuzako H., Hashiguchi T., Sakamoto Y., Okamura H., Doi W., Takenouchi K., Takigawa M. Metabolite changes with age measured by proton magnetic resonance spectroscopy in normal subjects. Psychiatry Clin. Neurosci. 51:1997;261-263.
76. Gadian D.G., Isaacs E.B., Cross J.H., Connelly A., Jackson G.D., King M.D., Neville B.G., Vargha-Khadem F. Lateralization of brain function in childhood revealed by magnetic resonance spectroscopy. Neurology. 46:1996;974-977.
77. Garnett M.R., Blamire A.M., Corkill R.G., Cadoux-Hudson T.A., Rajagopalan B., Styles P. Early proton magnetic resonance spectroscopy in normal-appearing brain correlates with outcome in patients following traumatic brain injury. Brain. 123:2000;2046-2054.
78. Garnett M.R., Blamire A.M., Rajagopalan B., Styles P., Cadoux-Hudson T.A. Evidence for cellular damage in normal-appearing white matter correlates with injury severity in patients following traumatic brain injury: a magnetic resonance spectroscopy study. Brain. 123:2000;1403-1409.
79. Gill S.S., Thomas D.G., van Bruggen N., Gadian D.G., Peden C.J., Bell J.D., Cox I.J., Menon D.K., Iles R.A., Bryant D.J. Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies. J. Comput. Assist. Tomogr. 14:1990;497-504.
80. Gonzalez R.G., Guimaraes A.R., Moore G.J., Crawley A., Cupples L.A., Growdon J.H. Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 10:1996;46-52.
81. Gray F., Scaravilli F., Everall I., Chretien F., An S., Boche D., Adle-Biassette H., Wingertsmann L., Durigon M., Hurtrel B., Chiodi F., Bell J., Lantos P. Neuropathology of early HIV-1 infection. Brain Pathol. 6:1996;1-15.
82. Harada M., Uno M., Hong F., Hisaoka S., Nishitani H., Matsuda T. Diffusion-weighted in vivo localized proton MR spectroscopy of human cerebral ischemia and tumor. NMR Biomed. 15:2002;69-74.
83. Helms G. Analysis of 1.5 Tesla proton MR spectra of human brain using LCModel and an imported basis set. Magn. Reson. Imaging. 17:1999;1211-1218.
84. Helms G. A precise and user-independent quantification technique for regional comparison of single volume proton MR spectroscopy of the human brain. NMR Biomed. 13:2000;398-406.
85. Heun R., Schlegel S., Graf-Morgenstern M., Tintera J., Gawehn J., Stoeter P. Proton magnetic resonance spectroscopy in dementia of Alzheimer type. Int. J. Geriatr. Psychiatry. 12:1997;349-358.
86. Hon J., Huppert F.A., Holland A.J., Watson P. Neuropsychological assessment of older adults with Down's syndrome: an epidemiological study using the Cambridge Cognitive Examination (CAMCOG). Br. J. Clin. Pyschol. 38:1999;155-165.
87. Houkin K., Kamada K., Kamiyama H., Iwasaki Y., Abe H., Kashiwaba T. Longitudinal changes in proton magnetic resonance spectroscopy in cerebral infarction. Stroke. 24:1993;1316-1321.
88. Hu M.T., Taylor-Robinson S.D., Chaudhuri K.R., Bell J.D., Morris R.G., Clough C., Brooks D.J., Turjanski N. Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. J. Neurol. Neurosurg. Psychiatry. 67:1999;20-26.
89. 1H MRS study. Am. J. Psychiatry. 156:1999;1866-1879.
90. 1H magnetic resonance spectroscopic imaging. Ann. Neurol. 40:1996;236-239.
91. Jarvik J.G., Lenkinski R.E., Saykin A.J., Jaans A., Frank I. Proton spectroscopy in asymptomatic HIV-infected adults: initial results in a prospective cohort study. J. Acquir. Immune Defic. Sydr. 13:1996;247-253.
92. Jessen F., Block W., Traber F., Keller E., Flacke S., Papassotiropoulos A., Lamerichs R., Heun R., Schild H.H. Proton MR spectroscopy detects a relative decrease of N-acetyl aspartate in the medial temporal lobe of patients with AD. Neurology. 55:2000;684-688.
93. Jessen F., Block W., Traber F., Keller E., Flacke S., Lamerichs R., Schild H.H., Heun R. Decrease of N-acetyl aspartate in the MTL correlates with cognitive decline of AD patients. Neurology. 57:2001;930-932.
94. Jokeit H., Ebner A. Long term effects of refractory temporal lobe epilepsy on cognitive abilities: a cross sectional study. J. Neurol. Neurosurg. Psychiatry. 67:1999;44-50.
95. Judd M.G., Nagaraja T.N., Brookes N. Potassium-induced stimulation of glutamate uptake in mouse cerebral astrocytes: the role of intracellular pH. J. Neurochem. 66:1996;169-176.
96. Jung R.E., Brooks W.M., Yeo R.A., Chiulli S.J., Weers D.C., Sibbitt W.L.J. Biochemical markers of intelligence: a proton MR spectroscopy study of normal human brain. Philos. Trans. R. Soc. Lond. B Biol. Sci. 266:1999;1375-1399.
97. Jung R.E., Yeo R.A., Chiulli S.J., Sibbitt W.L.J., Weers D.C., Hart B.L., Brooks W.M. Biochemical markers of cognition: a proton MR spectroscopy study of normal human brain. NeuroReport. 10:1999;3327-3331.
98. Jung R.E., Yeo R.A., Chiulli S.J., Sibbitt W.L.J., Brooks W.M. Myths of neuropsychology: intelligence, neurometabolism, and cognitive ability. Clin. Neuropsychol. 14:2000;535-545.
99. 1H MRS study. Neurology. 55:2000;210-217.
100. Kario K., Matsuo T., Hoshide S., Umeda Y., Shimada K. Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study. Stroke. 30:1999;1033-1037.
101. Kato T., Murashita J., Shioiri T., Inubushi T., Kato N. Relationship of energy metabolism detected by 31P-MRS in the human brain with mental fatigue. Neuropsychobiology. 39:1999;214-218.
102. Kattapong V.J., Brooks W.M., Wesley M.H., Kodituwakku P.W., Rosenberg G.A. Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch. Neurol. 53:1996;678-680.
103. 1H-MRS and function using several neuropsychological tests in temporal lobe epilepsy. Seizure. 10:2001;188-193.
104. Koshino Y., Murata T., Oomori M., Murata I., Horie T., Isaki K., Kimura H., Ishii Y. In vivo proton magnetic resonance spectroscopy in adult Down's syndrome. Biol. Psychiatry. 32:1992;625-627.
105. Leary S.M., Brex P.A., MacManus D.G., Parker G.J., Barker G.J., Miller D.H., Thompson A.J. A (1)H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. Mag. Res. Imaging. 18:2000;455-459.
106. Lopez-Villegas D., Lenkinski R.E., Frank I. Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 94:1997;9854-9859.
107. 18F-fluorodeoxyglucose positron emission tomography. Magn. Reson. Med. 37:1997;18-23.
108. 1H magnetic resonance spectroscopic imaging. Arch. Neurol. 53:1996;167-174.
109. Magistretti P.J., Pellerin L., Rothman D.L., Shulman R.G. Energy on demand. Science. 283:1999;496-497.
110. 1H MRS of brain. Magn. Res. Imaging. 14:1996;281-292.
111. 1H MRSI-detected hippocampal abnormalities in temporal lobe epilepsy. Neurology. 53:1999;2052-2058.
112. Masliah E., Ge N., Achim C.L., Hansen L.A., Wiley C.A. Selective neuronal vulnerability in HIV encephalitis. J. Neuropathol. Exp. Neurol. 51:1992;585-593.
113. 1H-MRS metabolic abnormalities in temporal lobe epilepsy. Epilepsia. 42:2001;417-422.
114. McConnell J.R., Swindells S., Ong C.S., Gmeiner W.H., Chu W.K., Brown D.K., Gendelman H.E. Prospective utility of cerebral proton magnetic resonance spectroscopy in monitoring HIV infection and its associated neurological impairment. AIDS Res. Hum. Retrovir. 10:1994;977-982.
115. Mecheri G., Marie-Cardine M., Sappey-Marinier D., Bonmartin H., Albrand G., Ferry G., Coppard-Meyer N., Courpron P. In vivo hippocampal 31P NMR metabolites in Alzheimer's disease and ageing. Eur. Psychiatry. 12:1997;140-148.
116. Menon D.K., Ainsworth J.G., Cox I.J., Coker R.C., Sargentoni J., Coutts G.A., Baudouin C.J., Kocsis A.E., Harris J.R. Proton MR spectroscopy of the brain in AIDS dementia complex. J. Comput. Assist. Tomogr. 16:1992;538-542.
117. Meyerhoff D.J., MacKay S., Poole N., Dillon W.P., Weiner M.W., Fein G. N-acetyl aspartate reductions measured by 1H MRSI in cognitively impaired HIV-seropositive individuals. Magn. Reson. Imaging. 12:1994;653-659.
118. Meyerhoff D.J., Bloomer C., Cardenas V., Norman D., Weiner M.W., Fein G. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology. 52:1999;995-1003.
119. Mielke R., Schopphoff H.H., Kugel H., Pietrzyk U., Heindel W., Kessler J., Heiss W.D. Relation between 1H MR spectroscopic imaging and regional cerebral glucose metabolism in Alzheimer's disease. Int. J. Neurosci. 107:2001;233-245.
120. 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci. 58:1996;1929-1935.
121. Miller S.P., Li L.M., Cendes F., Caramanos Z., Rosenblatt B., Shevell M.I., Andermann F., Arnold D.L. Neuronal dysfunction in children with newly diagnosed temporal lobe epilepsy. Pediatr. Neurol. 22:2000;281-286.
122. 31P MRS study of autism: evidence for undersynthesis and increased degradation of brain membranes. Biol. Psychiatry. 33:1993;762-773.
123. Moss H.B., Talagala S.L., Kirisci L. Phosphorus-31 magnetic resonance brain spectroscopy of children at risk for a substance use disorder: preliminary results. Psychiatry Res. 76:1997;101-112.
124. Mossakowski M.J., Zelman I.B. Neuropathological syndromes in the course of full blown acquired immune deficiency syndrome (AIDS) in adults in Poland (1987-1995). Folia Neuropathol. 35:1997;133-143.
125. Murata T., Koshino Y., Omori M., Murata I., Nishio M., Horie T., Umezawa Y., Isaki K., Kimura H., Itoh S. In vivo proton magnetic resonance spectroscopy study on premature aging in adult Down's syndrome. Biol. Psychiatry. 34:1993;290-297.
126. Murphy D.G., Bottomley P.A., Salerno J.A., DeCarli C., Mentis M.J., Grady C.L., Teichberg D., Giacometti K.R., Rosenberg J.M., Hardy C.J. An in vivo study of phosphorus and glucose metabolism in Alzheimer's disease using magnetic resonance spectroscopy and PET. Arch. Gen. Psychiatry. 50:1993;341-349.
127. Nakano M., Ueda H., Li J.Y., Matsumoto M., Yanagihara T. Measurement of regional N-acetyl aspartate after transient global ischemia in gerbils with and without ischemic tolerance: an index of neuronal survival. Ann. Neurol. 44:1998;334-340.
128. Namer I.J., Bolo N.R., Sellal F., Nguyen V.H., Nedelec J.F., Hirsch E., Marescaux C. Combined measurements of hippocampal N-acetyl-aspartate and T2 relaxation time in the evaluation of mesial temporal lobe epilepsy: correlation with clinical severity and memory performances. Epilepsia. 40:1999;1424-1432.
129. Nicolay K., Braun K.P., Graaf R.A., Dijkhuizen R.M., Kruiskamp M.J. Diffusion NMR spectroscopy. NMR Biomed. 14:2001;94-111.
130. 18F DG-PET. Magn. Reson. Med. 43:2000;244-250.
131. Park S.W., Chang K.H., Kim H.D., Song I.C., Lee D.S., Lee S.K., Chung C.K., Yu I.K., Han M.H., Park Y.H. Lateralizing ability of single-voxel proton mr spectroscopy in hippocampal sclerosis: comparison with mr imaging and positron emission tomography. Am. J. Neuroradiol. 22:2001;625-631.
132. 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease. J. Am. Geriatr. Soc. 44:1996;133-138.
133. Parnetti L., Tarducci R., Presciutti O., Lowenthal D.T., Pippi M., Palumbo B., Gobbi G., Pelliccioli G.P., Senin U. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech. Ageing Dev. 97:1997;9-14.
134. Pettegrew J.W., Panchalingam K., Klunk W.E., McClure R.J., Muenz L.R. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol. Aging. 15:1994;117-132.
135. Pettegrew J.W., Klunk W.E., Kanal E., Panchalingam K., McClure R.J. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol. Aging. 16:1995;973-975.
136. Pettegrew J.W., Klunk W.E., Panchalingam K., Kanfer J.N., McClure R.J. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol. Aging. 16:1995;1-4.
137. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E.V., Lim K.O. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch. Gen. Psychiatry. 56:1999;185-192.
138. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E.V., Lim K.O. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn. Reson. Med. 41:1999;276-284.
139. Posse S., Dager S.R., Richards T.L., Yuan C., Ogg R., Artru A.A., Muller-Gartner H.W., Hayes C. In vivo measurement of regional brain metabolic response to hyperventilation using magnetic resonance: proton echo planar spectroscopic imaging (PEPSI). Magn. Reson. Med. 37:1997;858-865.
140. Pouwels P.J., Frahm J. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed. 10:1997;73-78.
141. Pouwels P.J., Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn. Reson. Med. 39:1998;53-60.
142. Price J.L., Ko A.I., Wade M.J., Tsou S.K., McKeel D.W., Morris J.C. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 58:2001;1395-1402.
143. Prichard J., Rothman D., Novotny E., Petroff O., Kuwabara T., Avison M., Howseman A., Hanstock C., Shulman R. Lactate rise detected by 1H NMR in human visual cortex during physiologic stimulation. Proc. Nat. Acad. Sci. U. S. A. 88:1991;5829-5831.
144. Rae C., Scott R.B., Thompson C.H., Kemp G.J., Dumughn I., Styles P., Tracey I., Radda G.K. Is pH a biochemical marker of IQ? Proc. R. Soc. Lond. B Biol. Sci. 263:1996;1061-1064.
145. Rae C., Karmiloff-Smith A., Lee M.A., Dixon R.M., Grant J., Blamire A.M., Thompson C.H., Styles P., Radda G.K. Brain biochemistry in Williams syndrome: evidence for a role of the cerebellum in cognition? Neurology. 51:1998;33-40.
146. Rae C., Lee M.A., Dixon R.M., Blamire A.M., Thompson C.H., Styles P., Talcott J., Richardson A.J., Stein J.F. Metabolic abnormalities in developmental dyslexia detected by 1H magnetic resonance spectroscopy. Lancet. 351:1998;1849-1852.
147. Rajanayagam V., Balthazor M., Shapiro E.G., Krivit W., Lockman L., Stillman A.E. Proton MR spectroscopy and neuropsychological testing in adrenoleukodystrophy. Am. J. Neuroradiol. 18:1997;1909-1914.
148. Renshaw P.F., Yurgelun-Todd D.A., Tohen M., Gruber S., Cohen B.M. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am. J. Psychiatry. 152:1995;444-446.
149. Ricci R., Barbarella G., Musi P., Boldrini P., Trevisan C., Basaglia N. Localised proton MR spectroscopy of brain metabolism changes in vegetative patients. Neuroradiol. 39:1997;313-319.
150. Richards T.L., Dager S.R., Corina D., Serafini S., Heide A.C., Steury K., Strauss W., Hayes C.E., Abbott R.D., Craft S., Shaw D., Posse S., Berninger V.W. Dyslexic children have abnormal brain lactate response to reading-related language tasks. Am. J. Neuroradiol. 20:1999;1393-1398.
151. Richards T.L., Corina D., Serafini S., Steury K., Echelard D.R., Dager S.R., Marro K., Abbott R.D., Maravilla K.R., Berninger V.W. Effects of a phonologically driven treatment for dyslexia on lactate levels measured by proton MR spectroscopic imaging. Am. J. Neuroradiol. 21:2000;916-922.
152. 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn. Reson. Imaging. 17:1999;291-299.
153. 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn. Reson. Imaging. 17:1999;291-299.
154. Roser W., Hagberg G., Mader I., Brunnschweiler H., Radue E.W., Seelig J., Kappos L. Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter. Magn. Reson. Med. 33:1995;811-817.
155. Ross B., Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn. Reson. Q. 10:1994;191-247.
156. Ross B.D., Bluml S., Cowan R., Danielsen E., Farrow N., Gruetter R. In vivo magnetic resonance spectroscopy of human brain: the biophysical basis of dementia. Biophys. Chem. 68:1997;161-172.
157. 1H MRS in acute traumatic brain injury. J. Magn. Reson. Imaging. 8:1998;829-840.
158. Rothman D.L., Sibson N.R., Hyder F., Shen J., Behar K.L., Shulman R.G. In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:1999;1165-1177.
159. Rund B.R. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr. Bull. 24:1998;425-435.
160. 1H magnetic resonance spectroscopy study. J. Magn. Reson. Imaging. 11:2000;279-286.
161. Sager T.N., Fink-Jensen A., Hansen A.J. Transient elevation of interstitial N-acetyl aspartate in reversible global brain ischemia. J. Neurochem. 68:1997;675-682.
162. 1H-MRS and un-biased stereology: can non-invasive measures of N-acetyl-asparate following global ischemia be used as a reliable measure of neuronal damage? Brain Res. 892:2001;166-175.
163. Salvan A.M., Vion-Dury J., Confort-Gouny S., Nicoli F., Lamoureux S., Cozzone P.J. Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: identification of evolving metabolic patterns in relation to dementia and therapy. AIDS Res. Hum. Retrovir. 13:1997;1055-1066.
164. Salvan A.M., Vion-Dury J., Confort-Gouny S., Nicoli F., Lamoureux S., Cozzone P.J. Cerebral metabolic alterations in human immunodeficiency virus-related encephalopathy detected by proton magnetic resonance spectroscopy. Comparison between sequences using short and long echo times. Invest. Radiol. 32:1997;485-495.
165. Salvan A.M., Ceccaldi M., Confort-Gouny S., Milandre C., Cozzone P.J., Vion-Dury J. Correlation between cognitive status and cerebral inositol in Alzheimer-type dementia. J. Neurol. 245:1998;686-688.
166. Salvan A.M., Lamoureux S., Michel G., Confort-Gouny S., Cozzone P.J., Vion-Dury J. Localized proton magnetic resonance spectroscopy of the brain in children infected with human immunodeficiency virus with and without encephalopathy. Pediatr. Res. 44:1998;755-762.
167. Sarchielli P., Presciutti O., Pelliccioli G.P., Tarducci R., Gobbi G., Chiarini P., Alberti A., Vicinanza F., Gallai V. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain. 122:1999;513-521.
168. Saunders D.E., Howe F.A., van den B.A., Griffiths J.R., Brown M.M. Aging of the adult human brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy. J. Magn. Reson. Imaging. 9:1999;711-716.
169. Sauter A., Rudin M. Determination of creatine kinase kinetic parameters in rat brain by NMR magnetization transfer. Correlation with brain function. J. Biol. Chem. 268:1993;13166-13171.
170. Sawrie S.M., Martin R.C., Gilliam F.G., Faught R.E., Maton B., Hugg J.W., Bush N., Sinclair K., Kuzniecky R.I. Visual confrontation naming and hippocampal function: a neural network study using quantitative (1)H magnetic resonance spectroscopy. Brain. 123:2000;770-780.
171. Sawrie S.M., Martin R.C., Knowlton R., Faught E., Gilliam F., Kuzniecky R. Relationships among hippocampal volumetry, proton magnetic resonance spectroscopy, and verbal memory in temporal lobe epilepsy. Epilepsia. 42:2001;1403-1407.
172. Scheibel A., Conrad T., Perdue S., Tomiyasu U., Wechsler A. A quantitative study of dendrite complexity in selected areas of the human cerebral cortex. Brain Cogn. 12:1990;85-101.
173. Schmahmann J.D. An emerging concept. The cerebellar contribution to higher function. Arch. Neurol. 48:1991;1178-1187.
174. 1H magnetic resonance spectroscopic imaging. Magn. Reson. Med. 45:2001;899-907.
175. Serafini S., Steury K., Richards T., Corina D., Abbott R., Dager S.R., Berninger V. Comparison of fMRI and PEPSI during language processing in children. Magn. Reson. Med. 45:2001;217-225.
176. Serles W., Li L.M., Antel S.B., Cendes F., Gotman J., Olivier A., Andermann F., Dubeau F., Arnold D.L. Time course of postoperative recovery of N-acetyl-aspartate in temporal lobe epilepsy. Epilepsia. 42:2001;190-197.
177. 13C NMR. Proc. Natl. Acad. Sci. U. S. A. 96:1999;8235-8240.
178. Shim T.S., Lee J.H., Kim S.Y., Lim T.H., Kim S.J., Kim D.S., Kim W.D. Cerebral metabolic abnormalities in COPD patients detected by localized proton magnetic resonance spectroscopy. Chest. 120:2001;1506-1513.
179. Shioiri T., Kato T., Inubushi T., Murashita J., Takahashi S. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Res. 55:1994;223-235.
180. Shioiri T., Someya T., Murashita J., Kato T., Hamakawa H., Fujii K., Inubushi T. Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia. Psychiatry Res. 76:1997;113-122.
181. Shonk T.K., Moats R.A., Gifford P., Michaelis T., Mandigo J.C., Izumi J., Ross B.D. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology. 195:1995;65-72.
182. Shulman R.G. Functional imaging studies: linking mind and basic neuroscience. Am. J. Psychiatry. 158:2001;11-20.
183. Sibbitt W.L., Haseler L.J., Griffey R.R., Friedman S.D., Brooks W.M. Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy. Am. J. Neuroradiol. 18:1997;1271-1277.
184. Simmons M.L., Frondoza C.G., Coyle J.T. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience. 45:1991;37-45.
185. Sinson G., Bagley L.J., Cecil K.M., Torchia M., McGowan J.C., Lenkinski R.E., McIntosh T.K., Grossman R.I. Magnetization transfer imaging and proton MR spectroscopy in the evaluation of axonal injury: correlation with clinical outcome after traumatic brain injury. Am. J. Neuroradiol. 22:2001;143-151.
186. Stankoff B., Tourbah A., Suarez S., Turell E., Stievenart J.L., Payan C., Coutellier A., Herson S., Baril L., Bricaire F., Calvez V., Cabanis E.A., Lacomblez L., Lubetzki C. Clinical and spectroscopic improvement in HIV-associated cognitive impairment. Neurology. 56:2001;112-115.
187. 1H MR spectra. Magn. Reson. Med. 34:1995;17-24.
188. Stocchi F., Brusa L. Cognition and emotion in different stages and subtypes of Parkinson's disease. J. Neurol. 247:2000;21. (Suppl.).
189. Stoppe G., Bruhn H., Pouwels P.J., Hanicke W., Frahm J. Alzheimer disease: absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy. Alzheimer Dis. Assoc. Disord. 14:2000;112-119.
190. Suwanwelaa N., Phanuphak P., Phanthumchinda K., Suwanwela N.C., Tantivatana J., Ruxrungtham K., Suttipan J., Wangsuphachart S., Hanvanich M. Magnetic resonance spectroscopy of the brain in neurologically asymptomatic HIV-infected patients. Magn. Reson. Imaging. 18:2000;859-865.
191. Taylor D.L., Davies S.E., Obrenovitch T.P., Doheny M.H., Patsalos P.N., Clark J.B., Symon L. Investigation into the role of N-acetyl aspartate in cerebral osmoregulation. J. Neurochem. 65:1995;275-281.
192. Tracey I., Carr C.A., Guimaraes A.R., Worth J.L., Navia B.A., Gonzalez R.G. Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: a proton magnetic resonance spectroscopic study. Neurology. 46:1996;783-788.
193. Tsai G., Coyle J.T. N-acetyl aspartate in neuropsychiatric disorders. Prog. Neurobiol. 46:1995;531-540.
194. Urenjak J., Williams S.R., Gadian D.G., Noble M. Specific expression of N-acetyl aspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J. Neurochem. 59:1992;55-61.
195. Valenzuela M.J., Sachdev P.S., Wen W., Shnier R., Brodaty H., Gillies D. Dual voxel proton magnetic resonance spectroscopy in the healthy elderly: subcortical-frontal axonal N-acetyl aspartate levels are correlated with fluid cognitive abilities independent of structural brain changes. NeuroImage. 12:2000;747-756.
196. Vion-Dury J., Nicoli F., Salvan A.M., Confort-Gouny S., Dhiver C., Cozzone P.J. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet. 345:1995;60-61.
197. Vitkovic L., Tardieu M. Neuropathogenesis of HIV-1 infection. Outstanding questions. C. R. Acad. Sci., Ser. 3, Sci. Vie. 321:1998;1015-1021.
198. Volz H.P., Hubner G., Rzanny R., Rossger G., Preussler B., Eichhorn M., Kreitschmann-Andermahr I., Kaiser W.A., Sauer H. High-energy phosphates in the frontal lobe correlate with Wisconsin Card Sort Test performance in controls, not in schizophrenics: a 31-phosphorus magnetic resonance spectroscopic and neuropsychological investigation. Schizophr. Res. 31:1998;37-47.
199. Wexler B.E., Stevens A.A., Bowers A.A., Sernyak M.J., Goldman-Rakic P.S. Word and tone working memory deficits in schizophrenia. Arch. Gen. Psychiatry. 55:1998;1093-1096.
200. Wiedermann D., Schuff N., Matson G.B., Soher B.J., Du A.T., Maudsley A.A., Weiner M.W. Short echo time multislice proton magnetic resonance spectroscopic imaging in human brain: metabolite distributions and reliability. Magn. Reson. Imaging. 19:2001;1073-1080.
201. Wilkinson I.D., Lunn S., Miszkiel K.A., Miller R.F., Paley M.N., Williams I., Chinn R.J., Hall-Craggs M.A., Newman S.P., Kendall B.E., Harrison M.J. Proton MRS and quantitative MRI assessment of the short term neurological response to antiretroviral therapy in AIDS. J. Neurol. Neurosurg. Psychiatry. 63:1997;477-482.
202. Wilkinson I.D., Miller R.F., Miszkiel K.A., Paley M.N., Hall-Craggs M.A., Baldeweg T., Williams I.G., Carter S., Newman S.P., Kendall B.E., Catalan J., Chinn R.J., Harrison M.J. Cerebral proton magnetic resonance spectroscopy in asymptomatic HIV infection. AIDS. 11:1997;289-295.
203. 31P-spectroscopy of frontal lobe in schizophrenia: alterations in phospholipid and high-energy phosphate metabolism. Schizophr. Res. 58:2002;117-122.
204. Yeo R.A., Hill D., Campbell R., Vigil J., Brooks W.M. Developmental instability and working memory ability in children: a magnetic resonance spectroscopy investigation. Dev. Neuropsychol. 17:2000;143-159.
205. Yurgelun-Todd D.A., Renshaw P.F., Gruber S.A., Ed M., Waternaux C., Cohen B.M. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophr. Res. 19:1996;55-59.